Top Story Today
From First Date to Major ADC Bet: Gilead Goes All-In on Guided Missile Cancer Drugs
Gilead signed an exclusive option and license agreement with Tubulis worth up to approximately $465 million ($20 million upfront, a $30 million option fee, and up to $415 million in milestones) for the Munich-based antibody-drug conjugate developer. What caught Gilead's eye: a 59% response rate in platinum-resistant ovarian cancer, a notoriously stubborn disease. Tubulis will serve as Gilead's dedicated ADC research partner, keeping its team and labs intact. The deal cements Gilead's transformation from antiviral powerhouse to oncology heavyweight in a market where six ADC products already top $1 billion in annual sales.
Why it matters: With the ADC market projected to nearly triple by the early 2030s, Gilead's investment in next-generation linker technology signals that first-gen ADCs were just the appetizer, and pharma is now racing to own the main course.
Read more →Deals and M&A
Neurocrine Drops $2.9 Billion to Own the Only Drug for an Unstoppable Appetite
Neurocrine is paying $2.9 billion in all cash for Soleno Therapeutics and its Vykat XR, the only FDA-approved drug for the life-threatening hunger that defines Prader-Willi syndrome. The drug pulled in $190 million in its first year, with nearly half coming in Q4 alone. Some shareholders aren't thrilled: the stock once traded above $90, and law firms are already investigating whether $53 per share shortchanges investors.
Read more →Takeda Walks Away from Eight-Year Brain Drug Partnership with Denali
After eight years and $150 million upfront, Takeda handed back a promising dementia drug to Denali Therapeutics, citing "strategic considerations" (not safety problems). The move fits a broader pattern of big pharma reevaluating neuroscience commitments. Denali's stock actually rose on the news; Phase 1/2 data is expected by year-end.
Read more →Clinical and Regulatory
Sanofi's Two-Target Drug Aced the Lungs, Then Face-Planted on Skin
Sanofi's bispecific antibody lunsekimig delivered impressive results in asthma and nasal polyps, then missed its primary endpoint in eczema. The split verdict is a reality check for bispecific platforms: what works in the airways doesn't automatically translate to the skin, even when both diseases share the same inflammatory drivers. Sanofi will push forward in respiratory, but the dream of one drug ruling lungs and skin took a hit.
Read more →A Cancer-Killing Virus Faces a Make-or-Break FDA Decision This Week
Replimune's engineered herpes virus for advanced melanoma faces an April 10 FDA deadline after being rejected last year under murky circumstances. The official who blocked it? Gone. His replacement? Also gone. The agency has cycled through five CDER directors in a year, making this approval a litmus test for whether the FDA can still function amid unprecedented staff turnover.
Read more →The FDA Ghosted a Biotech Company. It Didn't Survive.
A four-month unexplained FDA scheduling delay drained investor confidence and killed Kezar Life Sciences, despite the company holding $90 million in cash and a drug that beat placebo in autoimmune hepatitis. When the meeting finally happened, it went well. By then, it didn't matter: 70% of staff had been laid off and the company was sold. Patients with AIH lost years of progress.
Read more →AI Meets Biology
Anthropic Paid $400M for a Biotech Startup With No Product and Fewer Than 10 Employees
The AI company behind Claude acquired Coefficient Bio, a stealth startup with zero revenue, for $400 million in stock. One early investor netted a 38,513% return in eight months. The real purchase: a team of computational biologists from Genentech's drug discovery unit who can teach AI to think like a biologist, not just summarize papers.
Read more →An AI Designed an Opioid Addiction Drug That Skips the Opioid Receptors Entirely
GATC Health's AI platform designed a drug candidate targeting serotonin receptors (not opioid receptors) for addiction, and it worked in rats: animals significantly reduced fentanyl self-administration and relapsed less. The compound is in preclinical development. With roughly one in four OUD patients receiving medication today, AI is now tackling a crisis that traditional pharma has largely avoided.
Read more →Biogen Bets on Shape-Shifting Genetic Medicines to Solve Its Delivery Problem
Biogen licensed Alloy Therapeutics' AntiClastic platform, which twists antisense oligonucleotides into cyclic shapes that show up to 50x improved potency in lab tests. The deal gives Biogen a potential fix for the delivery bottleneck plaguing genetic medicines. Sanofi already placed a $427.5 million bet on the same technology, validating the approach.
Read more →